deferasirox
Selected indexed studies
- Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota. (Life Sci, 2023) [PMID:36563842]
- Deferasirox. (Am J Health Syst Pharm, 2007) [PMID:17353569]
- Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload. (Vox Sang, 2021) [PMID:33529394]
_Worker-drafted node — pending editorial review._
Connections
deferasirox is a side effect of
Sources
- Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota. (2023) pubmed
- Deferasirox. (2007) pubmed
- Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload. (2021) pubmed
- Deferasirox nephrotoxicity-the knowns and unknowns. (2014) pubmed
- Deferasirox: pharmacokinetics and clinical experience. (2012) pubmed
- Deferasirox: A comprehensive drug profile. (2024) pubmed
- Deferasirox for managing iron overload in people with thalassaemia. (2017) pubmed
- Clinical pharmacology of deferasirox. (2014) pubmed
- Deferasirox for managing iron overload in people with myelodysplastic syndrome. (2014) pubmed
- Deferasirox desensitization. (2016) pubmed